hospitalization time in canine parvovirus infection. The drug may limit the ability of the virus to invade the crypt cells of the small intestine and decrease gastrointestinal bacterial colonization and toxin production. Research Oseltamivir has been deemed ineffective at treating COVID-19, consistent with the SARS-CoV-2 virus lacking influenza's neuraminidase enzyme. See also Amantadine and rimantadine – M2 inhibitors, for influenza treatment Baloxavir marboxil, an endonuclease inhibitor, for influenza treatment References Further reading External links Acetamides Cyclohexenes Dermatoxins Ethyl esters Hoffmann-La Roche brands Genentech brands Gilead Sciences Neuraminidase inhibitors Prodrugs Wikipedia medicine articles ready to translate World Health Organization essential medicines